Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Feb 2, 2018 (9 years ago)

Metformin Hydrochloride Tablets

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Presence of Foreign Tablet: Metformin BP 1000mg was found in bottle of Metformin HCl 1000mg

Cause type: Particulate / foreign matter

Visible foreign particles - glass, metal, fibers or other material - found in the product. Particles can enter from equipment wear, containers or the process, and are dangerous in injectables. All particulate / foreign matter recalls.

What was recalled

Metformin Hydrochloride Tablets, USP 1000 mg, 500-count bottles, Rx Only, Manufactured for: Aurobindo Pharma USA, Inc. 2400 Route 130 North Dayton, NJ 08810, Manufactured by: Aurobindo Pharma Limited Unit -VII (SEZ)) Mahabubnagar (Dt)_509302 India, NDC 65862-010-05.

Affected NDC 65862-0010-05

Compare with the code on your package — it is the most precise check available.

Drug: Metformin Category: Diabetes Medication

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Metformin Hydrochloride
NDC 65862-0010
1000 mg/1 Tablet, Film Coated
Oral
Aurobindo Pharma Limited Rx
Recalling firm
Aurobindo Pharma Ltd.
NDC code
65862-010-05
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0427-2018 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Metformin recalls

See all
Class II · Moderate risk

Synjardy XR Tablets

CGMP Deviations: An incorrect detergent was used and the required swab sampling was not performed on a production hopper that had previously been used for a different product.

Ongoing cGMP deviation Boehringer Ingelheim Pharmaceuticals, Inc. D-0657-2026

Other recalls by Aurobindo Pharma Ltd.

All 2018 recalls
Class II · Moderate risk

Acetaminophen Tablets

cGMP deviations: Due to confirmed consumer complaints received with the observation of tablet discoloration (brown surface on tablets).

Ongoing Failed specification Aurobindo Pharma USA Inc NDC 72288-405-10 D-0471-2025
Class II · Moderate risk

Nebivolol Tablets

CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso Nebivolol above acceptable intake (AI) limit.

Ongoing Nitrosamine impurity Aurobindo Pharma USA Inc D-0149-2025
Class II · Moderate risk

Cinacalcet Tablets

cGMP Deviations: Presence of N-nitroso Cinacalcet impurity above FDA recommended interim limit

Ongoing Nitrosamine impurity Aurobindo Pharma USA Inc NDC 65862-833-30 D-0079-2025